Tacrolimus and Hepatic lesion - a phase IV clinical study of FDA data

Summary:

Hepatic lesion is reported as a side effect among people who take Tacrolimus (tacrolimus), especially for people who are male, 60+ old, have been taking the drug for 1 - 6 months also take Mycophenolate Mofetil, and have Immunodeficiency disorders.

The phase IV clinical study analyzes which people have Hepatic lesion when taking Tacrolimus. It is created by eHealthMe based on reports of 115,828 people who have side effects when taking Tacrolimus from the FDA, and is updated regularly.

What is Tacrolimus?

Tacrolimus has active ingredients of tacrolimus. It is often used in kidney transplant. eHealthMe is studying from 116,161 Tacrolimus users. Check the latest studies of Tacrolimus.

What is Hepatic lesion?

Hepatic lesion is found to be associated with 672 drugs and 622 conditions by eHealthMe. Check the latest studies of Hepatic lesion.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 03, 2026

115,828 people reported to have side effects when taking Tacrolimus.
Among them, 47 people (0.04%) have Hepatic lesion.

Among these 47 people:

How long have people been on Tacrolimus when they have Hepatic lesion? *

What is the gender of people who have Hepatic lesion when taking Tacrolimus? *

female: 29.55 %
male: 70.45 %

What is the age of people who have Hepatic lesion when taking Tacrolimus? *

What are other drugs people take besides Tacrolimus? *

Mycophenolate Mofetil: 12 people, 25.53%
Everolimus: 8 people, 17.02%
Prednisolone: 7 people, 14.89%
Amlodipine: 7 people, 14.89%
Prednisone: 7 people, 14.89%
Cyclosporine: 5 people, 10.64%
Solu-Medrol: 3 people, 6.38%
Cyclophosphamide: 3 people, 6.38%
Fluconazole: 3 people, 6.38%
Bactrim Ds: 2 people, 4.26%

What are other side effects people have besides Hepatic lesion? *

Respiratory Acidosis (respiratory failure or ventilatory failure, causes the ph of blood and other bodily fluids to decrease): 17 people, 36.17%
Lymph Follicular Hypertrophy (an increase in the size of the lymph node follicles): 12 people, 25.53%
Disease Progression: 11 people, 23.40%
Pneumocystis Jiroveci Pneumonia (fungal infection of the lungs): 9 people, 19.15%
Cardiac Arrest: 9 people, 19.15%
Fever: 9 people, 19.15%
Epstein-Barr Virus Infection: 8 people, 17.02%
Pleural Effusion (water on the lungs): 8 people, 17.02%
Intestinal Obstruction: 7 people, 14.89%
Complications Of Transplanted Liver: 7 people, 14.89%

What are the existing conditions these people have? *

Immunodeficiency Disorders: 6 people, 12.77%
High Blood Pressure: 3 people, 6.38%
Post Transplant Lymphoproliferative Disorder: 2 people, 4.26%
Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 2 people, 4.26%
Stress And Anxiety: 1 person, 2.13%
Sepsis (a severe blood infection that can lead to organ failure and death): 1 person, 2.13%
Mucormycosis (a rare infection caused by organisms that belong to a group of fungi called mucoromycotina): 1 person, 2.13%
Hyperparathyroidism (an abnormally high concentration of parathyroid hormone in the blood, resulting in weakening of the bones through loss of calcium): 1 person, 2.13%
Hepatocellular Carcinoma (liver cancer): 1 person, 2.13%
Hepatoblastoma (liver cancer): 1 person, 2.13%

* Approximation only. Some reports may have incomplete information.

Do you take Tacrolimus and have Hepatic lesion?

- Check whether Hepatic lesion is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Tacrolimus:

Tacrolimus (116,161 reports)

Hepatic lesion treatments and more:

Hepatic lesion (5,726 reports)

Browse all side effects of Tacrolimus:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hepatic lesion:

Hepatic lesion (672 drugs)

Browse all the conditions that are associated with Hepatic lesion:

Hepatic lesion (622 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on tacrolimus (the active ingredients of Tacrolimus) and Tacrolimus (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.